Keywords: USA, FDA, Theravance, Astelas, Vibativ

US FDA says Theravance/Astellas’ Vibativ NDA for NP is incomplete

Article | 29 January 2010

US drug developer Theravance says that it has received from a letter from the Food and Drug Administration indicating that the firm’s response to the November 2009 Complete Response letter for the Vibativ (telavancin) New Drug Application for the treatment of nosocomial pneumonia (NP) is incomplete and that the review clock will not start until the FDA receives a complete response.

In aftermarket trading, Theravance shares lost 6% to $12.69. Enjoying this artcle? To continue reading you need to login, take a FREE trial or subscribe.

30 day FREE trial

Sign up in less than 60 seconds! No payment needed.

Want to read the full article?
Take a 30 day FREE Trial

Take a no obligations 30 day trial.
Only one trial per user. Find out more details

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in